• <table id="m4kmi"><option id="m4kmi"></option></table>
  • A POWERFUL RESEARCH AND
    DEVELOPMENT ENGINE

    Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

    • Phase 1 trials Phase 1 trials

      Phase 1 Trials

      CEMIPLIMAB*

      PD-1 Antibody Cancer

      REGN3767

      LAG-3 Antibody Cancer

      REGN1979

      CD20xCD3 Antibody Cancer

      REGN4018*

      MUC16xCD3 Antibody Cancer

      REGN4659

      CTLA4 Antibody Cancer
      REGN5093
      METxMET Antibody Cancer

      REGN5458*

      BCMAxCD3 Antibody Cancer
      REGN5459*
      BCMAxCD3 Antibody Cancer
      REGN5678
      PSMAxCD28 Antibody Cancer

      REGN3048-3051

      Middle East Respiratory Coronavirus Antibody MERS-CoV infection

      REGN4461

      LEPR Antibody Lipodystrophy and obesity
      REGN5713-5714-5715
      Betv1 Antibody Birch Allergy
    • Phase 2 trials Phase 2 trials

      Phase 2 Trials

      AFLIBERCEPT
      VEGF Trap High-dose for wet age-related macular degeneration (AMD)

      CEMIPLIMAB*

      PD-1 Antibody Basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC)
      REGN1979
      CD20xCD3 Antibody Relapsed/refractory follicular lymphoma

      DUPILUMAB*

      IL-4R Antibody Grass allergy, peanut allergy

      SARILUMAB*

      IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

      REGN1908-1909

      Fel d 1 Antibody Cat allergy

      REGN3500*

      IL-33 Antibody Asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis

      REGN5069

      GFRα3 Antibody Osteoarthritis knee pain

      GARETOSMAB

      Activin A Antibody Fibrodysplasia Ossificans Progressiva (FOP)

      EVINACUMAB

      ANGPTL-3 Antibody Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia

      POZELIMAB

      C5 Antibody Paroxysmal nocturnal hemoglobinuria
    • Phase 3 trials Phase 3 trials

      Phase 3 Trials

      AFLIBERCEPT
      VEGF Trap Retinopathy of Prematurity (ROP)

      ALIROCUMAB*

      PCSK9 Antibody Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics

      CEMIPLIMAB*

      PD-1 Antibody Non-small cell lung cancer (NSCLC), cervical cancer, cutaneous squamous cell carcinoma (CSCC) (adjuvant)

      REGN-EB3

      Ebola Virus Antibody Ebola virus infection

      DUPILUMAB*

      IL-4R Antibody Atopic dermatitis in pediatrics, asthma in pediatric, eosinophilic esophagitis, COPD

      SARILUMAB*

      IL-6R Antibody Polymyalgia rheumatica, giant cell arteritis

      EVINACUMAB

      ANGPTL-3 Antibody Homozygous familial hypercholesterolemia (HoFH)

      FASINUMAB?

      NGF Antibody Chronic pain from osteoarthritis of the knee or hip
    • IMMUNOLOGY & INFLAMMATORY DISEASES
    • ONCOLOGY
    • OPHTHALMOLOGY
    • RARE DISEASES
    • CARDIOVASCULAR/METABOLIC DISEASES
    • INFECTIOUS DISEASES
    • PAIN

    Trials Footnotes

    * in collaboration with Sanofi

    ? in collaboration with Teva and Mitsubishi Tanabe

    This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

    伊人久久大香线蕉综合